IP Library Granted Patent US 11,964,040
Granted Patent B2
US 11,964,040 · App. 16/760,635 · Granted Apr 23, 2024

Oral health composition comprising purified biosurfactants and/or their derivatives

Inventors: Sean Farmer (North Miami Beach, FL); Ken Alibek (Solon, OH)
Assignee: Locus Solutions IPCo, LLC
A61K8/64A61K8/60A61K8/69A61Q11/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,964,040
App. No.
16/760,635
Filed
Apr 30, 2020
Granted
Apr 23, 2024
Kind
B2
Art Unit
1612
USPC
424/52
Abstract

The present invention provides microbe-based products, as well as methods of their production and use, in oral health compositions. More specifically, the present invention provides materials and methods for enhancing and/or maintaining oral health using topical oral health compositions comprising microbial growth by-products, specifically, biosurfactants.

Claims (4)

1. A method for treating a gum disease, gingivitis and/or periodontal disease in a subject's oral cavity, the method comprising applying a composition consisting essentially of a purified sophorolipid component and a mannosylerythritol lipid to microbial biofilm that is present on a surface of the subject's oral cavity in need of said treatment, wherein said sophorolipid component comprises at least 70% by weight of an acidic form sophorolipid, and wherein the application of said composition causes removal of said biofilm, wherein said biofilm comprises Porphyromonas gingiva/is.

2. The method of claim 1 , wherein the subject is a human or a domesticated animal.

3. The method of claim 1 , wherein the acidic form sophorolipid is an unacetylated acidic sophorolipid, monoacetylated acidic sophorolipid, diacetylated acidic sophorolipid or a combination thereof.

4. The method of claim 1 , wherein the microbial biofilm further comprises Tannerella forsythia and/or Treponema denticola.